🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 16 of 173

  1. US 11878961

    Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11878023

    Compositions and methods for delivering pharmaceutical agents

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11878012

    Compositions and methods for treating traumatic brain injury

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11879019

    Dual-enzyme responsive peptides

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11879034

    Functionalization of polymer scaffolds

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11878002

    Methods and materials for using Ruminococcus gnavus or Clostridium sporogenes to treat gastrointestinal disorders

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11873291

    Quinoline cGAS antagonist compounds

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11872312

    Neuroprotective liposome compositions and methods for treatment of stroke

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11873288

    Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH)

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11873319

    Cyclic di-nucleotide induction of type I interferon

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11872092

    Methods for surgical guidance in breast cancer surgery and lymph node dissection using two or more implantation devices comprising a capsule and a population of ultrasound-switchable fluorophores incorporated in the capsule

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11872200

    GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11865122

    Estrogen therapy for brain gray matter atrophy and associated disability

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11866407

    Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11865286

    Active agent delivery devices and methods of using the same

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11865174

    Universal vaccine platform

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11865157

    Compositions and methods of targeting cancer stem cells

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11858884

    Compositions and methods for modulating gene or gene product in cells

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11858925

    GAS41 inhibitors and methods of use thereof

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11858956

    6-aza-nucleoside prodrugs as antiviral agents for treating virus infections

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11857701

    Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11858927

    Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11858953

    Compositions and methods for synthesis of phosphorylated molecules

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11859016

    Peptide having cytoprotective effect against environmental pollutant and use thereof

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11857697

    Compositions and methods for obtaining 3-dimensional lung-like epithelium and related uses thereof

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11857613

    Vaccine for prevention of necrotic enteritis in poultry

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11857651

    Compositions with doped titanium dioxide nanoparticles and methods of use

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11857343

    Microneedle fabrication and device implantation

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11850247

    Antiviral compounds

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11851711

    DNA methylation biomarkers for cancer diagnosing

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11851671

    Programmable assembly of virus composites for receptor-targeted gene delivery

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11851503

    Antiplasmodial compounds

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11851464

    Methods and compositions related to recombinant NEIL2

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11851436

    Fused bicyclic pyrimidine derivatives and uses thereof

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11850261

    Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11844816

    Compositions and methods for augmenting the nasal microbiome

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11844805

    Formulations of testosterone and methods of treatment therewith

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11845959

    Identification of factor that promotes human HSC self-renewal

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11844874

    Lyophilized polymer scaffold compositions, processes for preparation and use in anabolic wound repair

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11840536

    Heterocyclic inhibitors of PTPN11

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11839623

    Antiviral prodrugs and formulations thereof

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11839650

    Universal influenza vaccine targeting virus/host recognition

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11840690

    Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11839616

    Ocular pharmaceutical compositions

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11839615

    Compounds and methods for treating addiction and related disorders

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11839642

    Anti-angiogenin peptides, compositions, and methods of use

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11840540

    Dimers of covalent NFKB inhibitors

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11839619

    Methods for treatment of pediatric systemic mastocytosis

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.